BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mansour-Ghanaei F, Taheri A, Froutan H, Ghofrani H, Nasiri-Toosi M, Bagherzadeh AH, Farahvash MJ, Mirmomen S, Ebrahimi-Dariani N, Farhangi E, Pourrasouli Z. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006; 12(7): 1125-1128 [PMID: 16534857 DOI: 10.3748/wjg.v12.i7.1125] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Bergasa NV. The pruritus of cholestasis: From bile acids to opiate agonists: Relevant after all these years. Medical Hypotheses 2018;110:86-9. [DOI: 10.1016/j.mehy.2017.11.002] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
2 Trivedi HD, Lizaola B, Tapper EB, Bonder A. Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. The American Journal of Medicine 2017;130:744.e1-7. [DOI: 10.1016/j.amjmed.2017.01.037] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.6] [Reference Citation Analysis]
3 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009;50:291-308. [PMID: 19554543 DOI: 10.1002/hep.22906] [Cited by in Crossref: 850] [Cited by in F6Publishing: 705] [Article Influence: 65.4] [Reference Citation Analysis]
4 Abbasi A, Joharimoqaddam A, Faramarzi N, Khosravi M, Jahanzad I, Dehpour AR. Opioid receptors blockade modulates apoptosis in a rat model of cirrhotic cardiomyopathy. Ann Med Health Sci Res. 2014;4:404-409. [PMID: 24971217 DOI: 10.4103/2141-9248.133468] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
5 Stull C, Lavery MJ, Yosipovitch G. Advances in therapeutic strategies for the treatment of pruritus. Expert Opinion on Pharmacotherapy 2016;17:671-87. [DOI: 10.1517/14656566.2016.1127355] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
6 Zarrindast MR, Issazadeh Y, Rezaei N, Khakpai F. Possible involvement of the opioidergic system in the modulation of body temperature, jumping behavior and memory process in cholestatic and addicted mice. EXCLI J 2020;19:311-22. [PMID: 32256271 DOI: 10.17179/excli2019-2055] [Reference Citation Analysis]
7 Tajiri K, Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World J Gastroenterol 2017; 23(19): 3418-3426 [PMID: 28596678 DOI: 10.3748/wjg.v23.i19.3418] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
8 Siemens W, Xander C, Meerpohl JJ, Buroh S, Antes G, Schwarzer G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2016;11:CD008320. [PMID: 27849111 DOI: 10.1002/14651858.CD008320.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
9 Bergasa NV. Update on the Treatment of the Pruritus of Cholestasis. Clinics in Liver Disease 2008;12:219-34. [DOI: 10.1016/j.cld.2007.11.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
10 Kremer AE. What are new treatment concepts in systemic itch? Exp Dermatol 2019;28:1485-92. [DOI: 10.1111/exd.14024] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
11 Tandon P, Rowe BH, Vandermeer B, Bain VG. The Efficacy and Safety of Bile Acid Binding Agents, Opioid Antagonists, or Rifampin in the Treatment of Cholestasis-Associated Pruritus. Am J Gastroenterology 2007;102:1528-36. [DOI: 10.1111/j.1572-0241.2007.01200.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 76] [Article Influence: 7.5] [Reference Citation Analysis]
12 Rinaldi G. The Itch-Scratch Cycle: A Review of the Mechanisms. Dermatol Pract Concept 2019;9:90-7. [PMID: 31106010 DOI: 10.5826/dpc.0902a03] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
13 Treeprasertsuk S, Silachamroon U, Krudsood S, Huntrup A, Suwannakudt P, Vannaphan S, Wilairatana P. Ursodeoxycholic acid and artesunate in the treatment of severe falciparum malaria patients with jaundice. J Gastroenterol Hepatol 2010;25:362-8. [PMID: 19817958 DOI: 10.1111/j.1440-1746.2009.06007.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
14 Murray-Brown FL. Naltrexone for cholestatic itch: a systematic review. BMJ Support Palliat Care 2021;11:217-25. [PMID: 33692114 DOI: 10.1136/bmjspcare-2020-002801] [Reference Citation Analysis]
15 Langedijk JAGM, Beuers UH, Oude Elferink RPJ. Cholestasis-Associated Pruritus and Its Pruritogens. Front Med (Lausanne) 2021;8:639674. [PMID: 33791327 DOI: 10.3389/fmed.2021.639674] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kremer AE, Feramisco J, Reeh PW, Beuers U, Oude Elferink RP. Receptors, cells and circuits involved in pruritus of systemic disorders. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2014;1842:869-92. [DOI: 10.1016/j.bbadis.2014.02.007] [Cited by in Crossref: 58] [Cited by in F6Publishing: 47] [Article Influence: 7.3] [Reference Citation Analysis]
17 Linares JPA, Almario LA. Eficacia de la naltrexona en el tratamiento de prurito severo. Revista Colombiana de Anestesiología 2011;39:251-7. [DOI: 10.5554/rca.v39i2.91] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
18 Binder A, Koroschetz J, Baron R. Disease mechanisms in neuropathic itch. Nat Rev Neurol 2008;4:329-37. [DOI: 10.1038/ncpneuro0806] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
19 de Vries E, Bolier R, Goet J, Parés A, Verbeek J, de Vree M, Drenth J, van Erpecum K, van Nieuwkerk K, van der Heide F, Mostafavi N, Helder J, Ponsioen C, Oude Elferink R, van Buuren H, Beuers U; Netherlands Association for the Study of the Liver-Cholestasis Working Group. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology 2021;160:734-743.e6. [PMID: 33031833 DOI: 10.1053/j.gastro.2020.10.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
20 Dillon S, Tobias JD. Ondansetron to treat pruritus due to cholestatic jaundice. J Pediatr Pharmacol Ther 2013;18:241-6. [PMID: 24052788 DOI: 10.5863/1551-6776-18.3.241] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
21 Ständer S, Weisshaar E, Luger TA. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008;17:161-9. [PMID: 18070080 DOI: 10.1111/j.1600-0625.2007.00664.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
22 Volpicelli JR, Fenton M. Sustained-release naltrexone formulations for the treatment of alcohol and opioid dependence. Future Neurology 2006;1:389-98. [DOI: 10.2217/14796708.1.4.389] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
23 Bergasa NV. Pruritus in primary biliary cirrhosis: pathogenesis and therapy. Clin Liver Dis. 2008;12:385-406; x. [PMID: 18456187 DOI: 10.1016/j.cld.2008.02.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
24 Stancil SL, Abdel-Rahman S, Wagner J. Developmental Considerations for the Use of Naltrexone in Children and Adolescents. J Pediatr Pharmacol Ther 2021;26:675-95. [PMID: 34588931 DOI: 10.5863/1551-6776-26.7.675] [Reference Citation Analysis]
25 Kremer AE, Oude Elferink RP, Beuers U. Pathophysiology and current management of pruritus in liver disease. Clin Res Hepatol Gastroenterol. 2011;35:89-97. [PMID: 21809485 DOI: 10.1016/j.clinre.2010.10.007] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 6.0] [Reference Citation Analysis]
26 Phan NQ, Bernhard JD, Luger TA, Ständer S. Antipruritic treatment with systemic μ-opioid receptor antagonists: a review. J Am Acad Dermatol. 2010;63:680-688. [PMID: 20462660 DOI: 10.1016/j.jaad.2009.08.052] [Cited by in Crossref: 109] [Cited by in F6Publishing: 77] [Article Influence: 9.1] [Reference Citation Analysis]
27 Isa F, Turner GM, Kaur G, Kyte D, Slade A, Pankhurst T, Kerecuk L, Keeley T, Ferguson J, Calvert M. Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review. Health Qual Life Outcomes 2018;16:133. [PMID: 29976215 DOI: 10.1186/s12955-018-0951-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
28 Yamamoto A, Kuyama S, Kamei C, Sugimoto Y. Characterization of scratching behavior induced by intradermal administration of morphine and fentanyl in mice. European Journal of Pharmacology 2010;627:162-6. [DOI: 10.1016/j.ejphar.2009.10.066] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
29 Faramarzi N, Abbasi A, Tavangar SM, Mazouchi M, Dehpour AR. Opioid receptor antagonist promotes angiogenesis in bile duct ligated rats. J Gastroenterol Hepatol 2009;24:1226-9. [PMID: 19486259 DOI: 10.1111/j.1440-1746.2009.05794.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
30 Bunchorntavakul C, Reddy KR. Pruritus in chronic cholestatic liver disease. Clin Liver Dis 2012;16:331-46. [PMID: 22541702 DOI: 10.1016/j.cld.2012.03.010] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
31 Maruani A, Samimi M, Lorette G. [Prurigo]. Presse Med 2009;38:1099-105. [PMID: 19171455 DOI: 10.1016/j.lpm.2008.10.014] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
32 Agelopoulos K, Pereira MP, Wiegmann H, Ständer S. Cutaneous neuroimmune crosstalk in pruritus. Trends in Molecular Medicine 2022. [DOI: 10.1016/j.molmed.2022.03.005] [Reference Citation Analysis]
33 Bodnar RJ. Endogenous opiates and behavior: 2006. Peptides 2007;28:2435-513. [PMID: 17949854 DOI: 10.1016/j.peptides.2007.09.002] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.9] [Reference Citation Analysis]
34 Patel P, Patel K, Pandher K, Tareen RS. The Role of Psychiatric, Analgesic, and Antiepileptic Medications in Chronic Pruritus. Cureus 2021;13:e17260. [PMID: 34522555 DOI: 10.7759/cureus.17260] [Reference Citation Analysis]
35 Kremer AE, Beuers U, Oude-Elferink RP, Pusl T. Pathogenesis and treatment of pruritus in cholestasis. Drugs. 2008;68:2163-2182. [PMID: 18840005 DOI: 10.2165/00003495-200868150-00006] [Cited by in Crossref: 77] [Cited by in F6Publishing: 58] [Article Influence: 5.9] [Reference Citation Analysis]
36 Sikora M, Rakowska A, Olszewska M, Rudnicka L. The Use of Naltrexone in Dermatology. Current Evidence and Future Directions. Curr Drug Targets 2019;20:1058-67. [PMID: 30887922 DOI: 10.2174/1389450120666190318121122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Alallam A, Barth D, Heathcote EJ. Role of plasmapheresis in the treatment of severe pruritus in pregnant patients with primary biliary cirrhosis: case reports. Can J Gastroenterol 2008;22:505-7. [PMID: 18478137 DOI: 10.1155/2008/969826] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
38 Xander C, Meerpohl JJ, Galandi D, Buroh S, Schwarzer G, Antes G, Becker G. Pharmacological interventions for pruritus in adult palliative care patients. Cochrane Database Syst Rev 2013;:CD008320. [PMID: 23749733 DOI: 10.1002/14651858.CD008320.pub2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
39 Schlosburg JE, Boger DL, Cravatt BF, Lichtman AH. Endocannabinoid modulation of scratching response in an acute allergenic model: a new prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 2009;329:314-23. [PMID: 19168707 DOI: 10.1124/jpet.108.150136] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 4.5] [Reference Citation Analysis]
40 Bachewar NP, Thawani VR, Mali SN, Gharpure KJ, Shingade VP, Dakhale GN. Comparison of safety, efficacy, and cost effectiveness of benzyl benzoate, permethrin, and ivermectin in patients of scabies. Indian J Pharmacol 2009;41:9-14. [PMID: 20177574 DOI: 10.4103/0253-7613.48882] [Cited by in Crossref: 41] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
41 Sanjel B, Shim WS. Recent advances in understanding the molecular mechanisms of cholestatic pruritus: A review. Biochim Biophys Acta Mol Basis Dis 2020;1866:165958. [PMID: 32896605 DOI: 10.1016/j.bbadis.2020.165958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010;11:1673-82. [PMID: 20426711 DOI: 10.1517/14656566.2010.484420] [Cited by in Crossref: 78] [Cited by in F6Publishing: 61] [Article Influence: 6.5] [Reference Citation Analysis]